Analytical Data
-
Gene name
CD11a
- Application
-
Alternative Names
CD11a；CDC2L2；CDC2L3；PITSLREB；Cyclin-dependent kinase 11A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20701
-
Expression Region
150-336aa
-
AA Sequence
CIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEG
-
Molecular Weight
50.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD11a is a crucial component of the integrin family, specifically part of the leukocyte integrin LFA-1 (lymphocyte function-associated antigen-1), which plays a vital role in immune responses by facilitating the adhesion and migration of leukocytes to sites of inflammation. Research into CD11a recombinant proteins has gained significant attention due to their potential therapeutic applications in autoimmune diseases, cancer, and organ transplantation. Abnormalities in CD11a function can lead to impaired immune responses or contribute to inflammatory diseases, making it a valuable target for drug development. The generation of recombinant CD11a proteins allows for detailed studies of its structure-function relationships, providing insights into how it interacts with its ligands, such as ICAM-1 (intercellular adhesion molecule-1). This understanding can pave the way for novel therapeutic strategies aimed at modulating immune responses. Furthermore, engineering CD11a for enhanced binding characteristics or altered immunogenic profiles opens possibilities for its application in immunotherapy and vaccine development. The ongoing research into CD11a recombinant proteins not only elucidates its fundamental role in the immune system but also highlights its potential as a biomarker for disease progression and a target for innovative treatments.
